Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter

    VANCOUVER, Aug. 12 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company, today
announced that it has received CE Mark approval to begin marketing the
HemoStream(TM) Chronic Dialysis Catheter in Europe.
    This CE Mark approval follows Angiotech's announcement in August 2007
that it had received clearance from the U.S. Food and Drug Association (FDA)
to begin marketing HemoStream in the United States. In April of the same year,
Angiotech entered into an agreement with Rex Medical, LP that granted
Angiotech an exclusive license to market and distribute HemoStream worldwide.
    "This CE Mark approval is another example of the international acceptance
of Angiotech's technologies. With Rex Medical as our worldwide licensing
partner, we look forward to expanding HemoStream's availability in Europe as
well as in the United States," said Dr. William Hunter, President and CEO of

    About the HemoStream Chronic Dialysis Catheter

    Incidences of End Stage Renal Disease (ESRD) requiring dialysis are a
rapidly growing challenge in healthcare worldwide. When kidneys fail, function
of the kidneys can be partially replaced using a process called hemodialysis.
This process involves drawing blood out of the body, filtering it through a
large machine and then returning filtered blood back to the body. Chronic
dialysis catheters, such as HemoStream, are used as long-term vascular access
for hemodialysis. HemoStream may also be used as a temporary access while more
permanent options mature or become ready for use, such as surgically created
AV fistulas.

    About Rex Medical, LP

    Rex Medical, LP, based in Conshohocken, PA, is a privately held medical
device company specializing in developing, manufacturing and marketing of
minimally invasive medical devices targeted towards the cardiovascular, venous
access, endosurgery and oncology markets.

    About Angiotech

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit

    Note on Forward Looking Statements:

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities legislation.
Forward looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the second half of 2008 and
beyond, and our strategies or future actions, our targets, expectations for
our financial condition and the results of, or outlook for, our operations,
research development and product and drug development. Such forward looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be materially
different from any future results, events or developments expressed or implied
by such forward-looking statements.
    Many such risks, uncertainties and other factors are taken into account
as part of our assumptions underlying these forward-looking statements and
include, among others, the following: general economic and business
conditions, both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing products or our
ability to develop and commercialize future products; competition; existing
governmental regulations and changes in, or the failure to comply with,
governmental regulations; adverse results or unexpected delays in pre-clinical
and clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products sold by our partners;
decisions, and the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the requirement for
substantial funding to conduct research and development, to expand
manufacturing and commercialization activities or consummate acquisitions; and
any other factors that may affect performance. In addition, our business is
subject to certain operating risks that may cause the actual results expressed
or implied by the forward-looking statements in this press release to differ
materially from our actual results. These operating risks include: our ability
to attract and retain qualified personnel; our ability to successfully
complete preclinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain patent
protection for discoveries; loss of patent protection resulting from third
party challenges to our patents; commercialization limitations imposed by
patents owned or controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; our ability to continue to service our debt
obligations; and any other factors referenced in our annual information form
and other filings with the applicable Canadian securities regulatory
authorities or the Securities and Exchange Commission. Given these
uncertainties, assumptions and risk factors, readers are cautioned not to
place undue reliance on such forward looking statements. Except as required by
law, we disclaim any obligation to update any such factors or to publicly
announce the result of any revisions to any of the forward looking statements
contained in this press release to reflect future results, events or

    HemoStream(TM) is a trademark of Rex Medical, LP, used under license by
Angiotech Pharmaceuticals, Inc.

For further information:

For further information: Sage Baker, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-6933,

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890